BIOMAT Database Logo BIOMAT Database Logo

2-(Alkoxyaryl)-2-imidazoline monoamine oxidase inhibitors with antidepressant activity. 1978

M Harfenist, and F E Soroko, and G M McKenzie

Unlike the related noncyclic amidines which are broad-spectrum cestocides, a number of 2-imidazolines substituted in the 2 position by alkoxyaryl groups were not highly active in screening tests against the mouse tapeworms Hymenolepsis nana and Oochoristica symmetrica. Certain of the 2-(4-alkoxynaphthyl)-2-imidazolines and 2-(6-alkoxy-2-naphthyl)-2-imidzolines, however, had activity interpreted as antidepressant in the mouse. This activity paralleled in vitro irreversible inhibitory activity against mouse brain MAO for those where no substitution is present on the imidazoline ring. This irreversibility probably has a different origin from that postulated to explain the irreversible MAO inhibition of proparglic, cyclopropyl, and other "chemically reactive" MAO inhibitors.

UI MeSH Term Description Entries
D007093 Imidazoles Compounds containing 1,3-diazole, a five membered aromatic ring containing two nitrogen atoms separated by one of the carbons. Chemically reduced ones include IMIDAZOLINES and IMIDAZOLIDINES. Distinguish from 1,2-diazole (PYRAZOLES).
D008996 Monoamine Oxidase Inhibitors A chemically heterogeneous group of drugs that have in common the ability to block oxidative deamination of naturally occurring monoamines. (From Gilman, et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 8th ed, p414) MAO Inhibitor,MAO Inhibitors,Reversible Inhibitors of Monoamine Oxidase,Monoamine Oxidase Inhibitor,RIMA (Reversible Inhibitor of Monoamine Oxidase A),Reversible Inhibitor of Monoamine Oxidase,Inhibitor, MAO,Inhibitor, Monoamine Oxidase,Inhibitors, MAO,Inhibitors, Monoamine Oxidase
D001921 Brain The part of CENTRAL NERVOUS SYSTEM that is contained within the skull (CRANIUM). Arising from the NEURAL TUBE, the embryonic brain is comprised of three major parts including PROSENCEPHALON (the forebrain); MESENCEPHALON (the midbrain); and RHOMBENCEPHALON (the hindbrain). The developed brain consists of CEREBRUM; CEREBELLUM; and other structures in the BRAIN STEM. Encephalon
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D000928 Antidepressive Agents Mood-stimulating drugs used primarily in the treatment of affective disorders and related conditions. Several MONOAMINE OXIDASE INHIBITORS are useful as antidepressants apparently as a long-term consequence of their modulation of catecholamine levels. The tricyclic compounds useful as antidepressive agents (ANTIDEPRESSIVE AGENTS, TRICYCLIC) also appear to act through brain catecholamine systems. A third group (ANTIDEPRESSIVE AGENTS, SECOND-GENERATION) is a diverse group of drugs including some that act specifically on serotonergic systems. Antidepressant,Antidepressant Drug,Antidepressant Medication,Antidepressants,Antidepressive Agent,Thymoanaleptic,Thymoanaleptics,Thymoleptic,Thymoleptics,Antidepressant Drugs,Agent, Antidepressive,Drug, Antidepressant,Medication, Antidepressant
D013329 Structure-Activity Relationship The relationship between the chemical structure of a compound and its biological or pharmacological activity. Compounds are often classed together because they have structural characteristics in common including shape, size, stereochemical arrangement, and distribution of functional groups. Relationship, Structure-Activity,Relationships, Structure-Activity,Structure Activity Relationship,Structure-Activity Relationships
D013747 Tetrabenazine A drug formerly used as an antipsychotic and treatment of various movement disorders. Tetrabenazine blocks neurotransmitter uptake into adrenergic storage vesicles and has been used as a high affinity label for the vesicle transport system. Nitoman,Xenazine
D051379 Mice The common name for the genus Mus. Mice, House,Mus,Mus musculus,Mice, Laboratory,Mouse,Mouse, House,Mouse, Laboratory,Mouse, Swiss,Mus domesticus,Mus musculus domesticus,Swiss Mice,House Mice,House Mouse,Laboratory Mice,Laboratory Mouse,Mice, Swiss,Swiss Mouse,domesticus, Mus musculus
D066298 In Vitro Techniques Methods to study reactions or processes taking place in an artificial environment outside the living organism. In Vitro Test,In Vitro Testing,In Vitro Tests,In Vitro as Topic,In Vitro,In Vitro Technique,In Vitro Testings,Technique, In Vitro,Techniques, In Vitro,Test, In Vitro,Testing, In Vitro,Testings, In Vitro,Tests, In Vitro,Vitro Testing, In

Related Publications

M Harfenist, and F E Soroko, and G M McKenzie
Novel monoamine oxidase inhibitors based on the privileged 2-imidazoline molecular framework.
January 2019, Bioorganic & medicinal chemistry letters,
M Harfenist, and F E Soroko, and G M McKenzie
Relationship between imidazoline(2) sites and monoamine oxidase.
December 2003, Annals of the New York Academy of Sciences,
M Harfenist, and F E Soroko, and G M McKenzie
Monoamine oxidase inhibitors. A review of antidepressant effectiveness.
July 1979, Archives of general psychiatry,
M Harfenist, and F E Soroko, and G M McKenzie
Monoamine oxidase inhibitors (MAOI) or reversible inhibitors of monoamine oxidase (RIMA)/tricyclic antidepressant (TCA) combination therapy.
June 1992, The Australian and New Zealand journal of psychiatry,
M Harfenist, and F E Soroko, and G M McKenzie
2-Hydroxy-2-phenylethylhydrazine monoamine oxidase inhibitors.
May 1969, Journal of medicinal chemistry,
M Harfenist, and F E Soroko, and G M McKenzie
Antidepressant monoamine oxidase inhibitors enhance serotonin but not norepinephrine neurotransmission.
January 1987, Psychopharmacology series,
M Harfenist, and F E Soroko, and G M McKenzie
Selective inhibitors of monoamine oxidase. 3. Structure-activity relationship of tricyclics bearing imidazoline, oxadiazole, or tetrazole groups.
April 1996, Journal of medicinal chemistry,
M Harfenist, and F E Soroko, and G M McKenzie
Proceedings: Mechanism of antidepressant efficacy of monoamine oxidase inhibitors: inhibition of monoamine oxidase or of catecholamine reuptake.
October 1974, Psychopharmacology bulletin,
M Harfenist, and F E Soroko, and G M McKenzie
Structure-activity relationships of monoamine oxidase inhibitors.
August 1973, Journal of medicinal chemistry,
M Harfenist, and F E Soroko, and G M McKenzie
Chills with monoamine oxidase inhibitors.
December 1983, Journal of clinical psychopharmacology,
Copied contents to your clipboard!